xanthelasma palpebrarum
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years, regardless of gender; 2. Fitzpatrick Skin Type II-V; 3. Palpebral xanthoma; 4. Patients who agreed to take photographs of the treatment area during the course of the study; 5. Patients who knew the study well and voluntarily signed the informed consent form before participating in the study, and were able to follow the expected treatment procedure and complete all follow-up visits.
Exclusion criteria
Exclusion criteria: 1. Patients who are sensitive to visible and near-infrared light; 2. Patients with a history of photosensitive epilepsy; 3. Patients whose skin had not returned to normal or whose skin was in a sensitive state before treatment; 4. Patients with squamous-cell carcinoma or melanoma or those with skin cancer in the intended area of treatment; 5. Known cases of coagulopathy or thromboembolism; 6. Patients who have taken or are taking anticoagulants or medications that affect wound healing in the past 6 months; 7. Patients who have taken or are taking drugs known to increase light sensitivity, such as psoralen, in the past 6 months; 8. Patients with a history of immunosuppressive disorders, including HIV infection or AIDS, or who have taken immunosuppressive drug; 9. Patients with active Human herpesvirus 1 (HSV) in the expected treatment area; 10. Patients with active local or systemic infection or open wounds in the area to be treated; 11. Patients who were enrolled in other clinical trials (other than registry studies) within 6 months before screening; 12. Pregnant or lactating patients; 13. The researchers considered that the patients with poor compliance or other organic diseases were not suitable to participate in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The clearance rate; | — |
Countries
China
Contacts
Hospital of Dermatology, Chinese Academy of Medical Sciences